Keeping Track: Mitsubishi ALS NDA; Opko’s Rayaldee Approval; Avycaz Label Extension
Executive Summary
The latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
Regeneron’s CRL For High-Dose Eylea Benefits Roche, Vabysmo
Although the US FDA complete response letter only cites third-party manufacturing issues, analysts say the delayed approval of 8mg Eylea could continue a competitive advantage for Vabysmo into 2024.
Keeping Track: Neurology And Breakthroughs Stay In Spotlight As US FDA Approves Radicava, Imfinzi; TaiMed Submits Ibalizumab
The latest drug development news and highlights from our Performance Tracker.
Keeping Track: A Blizzard Of Submissions And A Small Flurry Of Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.